Gyre Therapeutics plans to fully acquire Cullgen in Q2 2026 and will propose issuance of common shares upon conversion of Series B convertible preferred stock at the shareholders meeting.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2160","jir_company_name":"GNI Group, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-17","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/2160-20260417-01.pdf","jir_short_summary":"Gyre Therapeutics plans to fully acquire Cullgen in Q2 2026 and will propose issuance of common shares upon conversion of Series B convertible preferred stock at the shareholders meeting.","jir_summary":"### Overview of M&A\nGyre Therapeutics, a consolidated subsidiary of GNI Group, Inc., will submit a proposal regarding the share exchange acquisition plan for the full acquisition of Cullgen Inc. at its annual shareholders meeting scheduled for June 10, 2026. Under the acquisition scheme, Cullgen shareholders will receive Gyre Therapeutics common shares and Series B convertible preferred shares, with the preferred shares convertible to common shares under certain conditions. Due to Nasdaq listing rules requiring shareholder approval for issuance exceeding 20% of common shares, the number of shares issued before approval will be limited to 19.99% or less.\n\n### Impact on Shareholders and Future Outlook\nThis acquisition proposal is subject to approval at Gyre Therapeutics\u2019 annual shareholders meeting, and the impact on the Company's consolidated financial results is currently under review. Any changes or new disclosures related to this matter will be promptly announced. The acquisition completion is scheduled for early Q2 2026.","jir_financial_highlights":"Gyre Therapeutics Common Stock Issuance Ratio: Up to 19.99% (Number of issued common shares and voting rights limited to 19.99% or less before shareholder approval)\nScheduled Acquisition Date: Early Q2 2026 (Unknown)\nGyre Therapeutics Shareholders Meeting Date: June 10, 2026 (local time) (Unknown)","jir_category":"","jir_hashtags":"#GNIGroupInc, #M&A, #JapaneseStocks","jir_key_figures":"Gyre Therapeutics Common Stock Issuance Ratio: Up to 19.99% (Cap before shareholder approval)\nGyre Therapeutics Annual Shareholders Meeting Date: June 10, 2026 (local time)\nScheduled Completion of Cullgen Acquisition: Early Q2 2026","jir_meta_title":"\u3010GNI Group, Inc.\u3011Gyre Therapeutics Plans Full Acquisition of Cullgen\uff5cApril 2026","jir_meta_description":"Gyre Therapeutics, a consolidated subsidiary of GNI Group, Inc., has submitted a shareholders meeting notice regarding the full acquisition of Cullgen Inc. The acquisition is scheduled to complete in Q2 2026, with issuance of common shares subject to shareholder approval.","jir_og_title":"\u3010GNI Group, Inc.\u3011Gyre Therapeutics Plans Full Acquisition of Cullgen\uff5cApril 2026","jir_og_description":"Gyre Therapeutics filed a shareholders meeting notice for the acquisition of Cullgen. The acquisition is scheduled for completion in Q2 2026, with common shares to be issued following shareholder approval.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9370,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-41188","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n